Clinical response to navitoclax inversely correlated with MCL1 expression in CLL cells, and was positively associated with higher expression of BIM[37], a BH3-only protein that is liberated by BCL2 inhibition, neutralises MCL1 and directly activates BAX/BAK[64]. This evidence concerns the gene BAK1 and B-cell chronic lymphocytic leukemia.